Comparative evaluation of the efficacy of subgingival application of i-PRF as adjunctive therapy to SRP in treatment of smoker versus non-smoker patients with Periodontitis: A split-mouth, randomized controlled clinical trial.

Periodontitis is a chronic inflammatory disease that can lead to progressive destruction of periodontal tissues. Smoking is a major risk factor that negatively influences the outcome of periodontal therapy. Injectable platelet-rich fibrin (i-PRF), a second-generation platelet concentrate, has shown potential in promoting periodontal healing and regeneration. This randomized, split-mouth clinical trial aims to compare the efficacy of subgingival application of i-PRF as an adjunctive therapy to scaling and root planing (SRP) in smoker and non-smoker patients with periodontitis. Clinical parameters including probing pocket depth, clinical attachment level, and bleeding on probing will be evaluated as primary outcomes, while plaque index, gingival index, and gingival bleeding index will be assessed as secondary outcomes over a follow-up period of 3 months.